337 related articles for article (PubMed ID: 35636069)
21. Improved Health Outcomes from Hepatitis C Treatment Scale-Up in Spain's Prisons: A Cost-Effectiveness Study.
Dalgic OO; Samur S; Spaulding AC; Llerena S; Cobo C; Ayer T; Roberts MS; Crespo J; Chhatwal J
Sci Rep; 2019 Nov; 9(1):16849. PubMed ID: 31727921
[TBL] [Abstract][Full Text] [Related]
22. Understanding facilitators and barriers of direct-acting antiviral therapy for hepatitis C virus infection in prison.
Lafferty L; Rance J; Grebely J; Lloyd AR; Dore GJ; Treloar C;
J Viral Hepat; 2018 Dec; 25(12):1526-1532. PubMed ID: 30141261
[TBL] [Abstract][Full Text] [Related]
23. Hepatitis C Virus Reinfection Following Direct-Acting Antiviral Treatment in the Prison Setting: The SToP-C Study.
Carson JM; Dore GJ; Lloyd AR; Grebely J; Byrne M; Cunningham E; Amin J; Vickerman P; Martin NK; Treloar C; Martinello M; Matthews GV; Hajarizadeh B;
Clin Infect Dis; 2022 Nov; 75(10):1809-1819. PubMed ID: 35362522
[TBL] [Abstract][Full Text] [Related]
24. Continuum of hepatitis C care cascade in prison and following release in the direct-acting antivirals era.
Hariri S; Sharafi H; Sheikh M; Merat S; Hashemi F; Azimian F; Tamadoni B; Ramazani R; Gouya MM; Abbasi B; Tashakorian M; Alasvand R; Alavian SM; Poustchi H; Malekzadeh R
Harm Reduct J; 2020 Oct; 17(1):80. PubMed ID: 33081794
[TBL] [Abstract][Full Text] [Related]
25. Hepatitis C Virus Elimination Program among Prison Inmates, Israel.
Eisen L; Mor Z; Madar M; Rabinovitch R; Dadon Y; Sheffer R; Kaliner E; Goldstein L
Emerg Infect Dis; 2023 Nov; 29(11):2358-2361. PubMed ID: 37877627
[TBL] [Abstract][Full Text] [Related]
26. Outcomes of treatment for hepatitis C in prisoners using a nurse-led, statewide model of care.
Papaluca T; McDonald L; Craigie A; Gibson A; Desmond P; Wong D; Winter R; Scott N; Howell J; Doyle J; Pedrana A; Lloyd A; Stoove M; Hellard M; Iser D; Thompson A
J Hepatol; 2019 May; 70(5):839-846. PubMed ID: 30654067
[TBL] [Abstract][Full Text] [Related]
27. Violence and hepatitis C transmission in prison-A modified social ecological model.
Sazzad HMS; McCredie L; Treloar C; Lloyd AR; Lafferty L
PLoS One; 2020; 15(12):e0243106. PubMed ID: 33259565
[TBL] [Abstract][Full Text] [Related]
28. Who goes first? Understanding hepatitis C risk among injecting networks in the prison setting.
Lafferty L; Rance J; Treloar C
Drug Alcohol Depend; 2018 Feb; 183():96-101. PubMed ID: 29245104
[TBL] [Abstract][Full Text] [Related]
29. Outcomes of a nurse-led model of care for hepatitis C assessment and treatment with direct-acting antivirals in the custodial setting.
Overton K; Clegg J; Pekin F; Wood J; McGrath C; Lloyd A; Post JJ
Int J Drug Policy; 2019 Oct; 72():123-128. PubMed ID: 30967329
[TBL] [Abstract][Full Text] [Related]
30. Hepatitis C elimination among people incarcerated in prisons: challenges and recommendations for action within a health systems framework.
Akiyama MJ; Kronfli N; Cabezas J; Sheehan Y; Thurairajah PH; Lines R; Lloyd AR;
Lancet Gastroenterol Hepatol; 2021 May; 6(5):391-400. PubMed ID: 33857445
[TBL] [Abstract][Full Text] [Related]
31. Prevalence of human immunodeficiency virus, hepatitis B virus, hepatitis C virus and syphilis among prison inmates and officers at Nsawam and Accra, Ghana.
Adjei AA; Armah HB; Gbagbo F; Ampofo WK; Quaye IKE; Hesse IFA; Mensah G
J Med Microbiol; 2006 May; 55(Pt 5):593-597. PubMed ID: 16585647
[TBL] [Abstract][Full Text] [Related]
32. "That was quick, simple, and easy": Patient perceptions of acceptability of point-of-care hepatitis C RNA testing at a reception prison.
Lafferty L; Cochrane A; Sheehan Y; Treloar C; Grebely J; Lloyd AR
Int J Drug Policy; 2022 Jan; 99():103456. PubMed ID: 34560624
[TBL] [Abstract][Full Text] [Related]
33. The role of prison-based interventions for hepatitis C virus (HCV) micro-elimination among people who inject drugs in Montréal, Canada.
Godin A; Kronfli N; Cox J; Alary M; Maheu-Giroux M
Int J Drug Policy; 2021 Feb; 88():102738. PubMed ID: 32278651
[TBL] [Abstract][Full Text] [Related]
34. Telementoring for hepatitis C treatment in correctional facilities.
Neuhaus M; Langbecker D; Caffery LJ; Taylor M; Garner L; Williams G; Smith AC; Macdonald GA
J Telemed Telecare; 2018 Dec; 24(10):690-696. PubMed ID: 30343659
[TBL] [Abstract][Full Text] [Related]
35. Surveillance and prevention of hepatitis C in Australian prisons.
Dolan K
Can HIV AIDS Policy Law Newsl; 2000; 5(2-3):68-9. PubMed ID: 11833205
[TBL] [Abstract][Full Text] [Related]
36. [Hepatitis C in prisons : Treatment and barriers to the elimination goals of the United Nations].
Dichtl A; Jamin D; Stöver H; Grabski M; Knorr B
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2024 Jan; 67(1):36-44. PubMed ID: 38155308
[TBL] [Abstract][Full Text] [Related]
37. Barriers and advocacy needs for hepatitis C services in prisons: Informing the prisons hepatitis C advocacy toolkit.
Walker SJ; Shrestha LB; Lloyd AR; Dawson O; Sheehan Y; Sheehan J; Maduka NBC; Cabezas J; Akiyama MJ; Kronfli N;
Int J Drug Policy; 2024 Apr; 126():104386. PubMed ID: 38492433
[TBL] [Abstract][Full Text] [Related]
38. Incidence of hepatitis C virus infection in the prison setting: The SToP-C study.
Hajarizadeh B; Carson JM; Byrne M; Grebely J; Cunningham E; Amin J; Vickerman P; Martin NK; Treloar C; Martinello M; Lloyd AR; Dore GJ;
J Viral Hepat; 2024 Jan; 31(1):21-34. PubMed ID: 37936544
[TBL] [Abstract][Full Text] [Related]
39. Offering HCV treatment to prisoners is an important opportunity: key principles based on policy and practice assessment in Europe.
Stöver H; Meroueh F; Marco A; Keppler K; Saiz de la Hoya P; Littlewood R; Wright N; Nava F; Alam F; Walcher S; Somaini L
BMC Public Health; 2019 Jan; 19(1):30. PubMed ID: 30621658
[TBL] [Abstract][Full Text] [Related]
40. Prevalence of HCV in prisons in Wales, UK and the impact of moving to opt-out HCV testing.
Perrett SE; Plimmer A; Shankar AG; Craine N
J Public Health (Oxf); 2020 May; 42(2):423-428. PubMed ID: 32090269
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
